UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041007 |
|---|---|
| Receipt number | R000046815 |
| Scientific Title | Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis. |
| Date of disclosure of the study information | 2020/07/05 |
| Last modified on | 2020/07/05 21:20:07 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.
Acronym
Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.
Scientific Title
Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.
Scientific Title:Acronym
Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.
Region
| Japan |
Condition
Condition
Acute respiratory distress syndrome
Classification by specialty
| Pneumology | Intensive care medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assess the benefit and harms of steroids versus placebo or conservative therapy for patients with acute respiratory distress
Basic objectives2
Others
Basic objectives -Others
N/A
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
Hospital mortality, the number of ventilator free days, and incidence of infection.
If there will be no data of hospital mortality, we will collect 28-60days mortality as short-term mortality. Incidence of infection will collect data of the number of patients with infection during hospital stay. Hospital mortality and incidence of infection will integrate risk ratio. VFDs will integrate mean difference.
Key secondary outcomes
ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator days and oxygenation.
We will collect data of P/F ratio on study day 7 as oxygenation. ICU mortality will integrate risk ratio. ICU LOS, hospital LOS, ventilator days and P/F ratio will integrate mean difference.
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with ARDS, which was diagnosed by American European Consensus (1994) or Berlin (2012) diagnosis criteria. We will also include patients with acute respiratory failure which is defined as follow:
- An acute onset of hypoxemia, with P/F ratio 200 mmHg and less
- Bilateral noncardiogenic pulmonary edema
- No clinical evidence of increased left atrial hypertension or a pulmonary artery wedge pressure 18 mmHg and less in the presence of a pulmonary artery catheter.
Key exclusion criteria
- Cardiac edema
- Hypercapnia without hypoxia
- Contraindication of steroids
- Diseases which steroids is effective
- History of steroids use by some months before inclusion
- No ventilation
- Acute lung injury associated with immaturity and congenital malformations
Target sample size
0
Research contact person
Name of lead principal investigator
| 1st name | Shodai |
| Middle name | |
| Last name | Yoshihiro |
Organization
JA General Hospital
Division name
Pharmaceutical department
Zip code
738-8503
Address
1-3-3 jigozen, hatsukaiti-shi, HIROSHIMA 738-8503 JAPAN
TEL
0829-36-3111
syoshihiro-ja@umin.ac.jp
Public contact
Name of contact person
| 1st name | Shodai |
| Middle name | |
| Last name | Yoshihiro |
Organization
JA General Hospital
Division name
Pharmaceutical department
Zip code
738-8503
Address
1-3-3 jigozen, hatsukaiti-shi, HIROSHIMA 738-8503 JAPAN
TEL
0829-36-3111
Homepage URL
syoshihiro-ja@umin.ac.jp
Sponsor or person
Institute
JA General Hospital.
Institute
Department
Personal name
Funding Source
Organization
N/A.
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Pharmaceutical department, JA General Hospital
Address
1-3-3 jigozen, hatsukaiti-shi, HIROSHIMA 738-8503 JAPAN
Tel
0829-36-3111
syoshihiro-ja@umin.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 07 | Month | 05 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2020 | Year | 06 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2020 | Year | 07 | Month | 05 | Day |
Last follow-up date
| 2020 | Year | 07 | Month | 05 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
1. Types of study to be included.
We will include any randomized controlled trials.
2. Searches.
The following electronic database will be used; MEDLINE, CENTRAL, and ICHUSHI Web.
3. Risk of bias assessment.
Risk of bias will be classified as high, low or unclear by 2 or more reviewers. Any disagreements are resolved by discussion among reviewers. We will assess selection performance, detection attrition and reporting bias, and other potential risks of bias.
4. Strategy for data synthesis.
4.1. Summary measures
Collected variables will be synthesized by using random-effects methods. We will create a 'Summary of findings table' using follow seven outcomes; hospital mortality, VFDs, incidence of infection, ICU mortality, ICU LOS, hospital LOS, and data of P/F ratio. Each outcomes will be checked the certainty of the evidence by risk of bias, inconsistency/heterogeneity, indirectness, imprecision and publication bias. Our conclusion will be presented by a Summary of findings table.
4.2. Assessment of heterogeneity
We will assess heterogeneity by using visual inspection of forest plot, I2 statics and Cochran's Q statistic.
4.3. Subgroup analysis
We will conduct subgroup analysis about timing, anti-inflammatory potency, duration of steroids and age for the primary outcomes. The anti-inflammatory potency will be divided into three categories of methylprednisolone equivalents. We will categorize duration of steroids by considering half-life of steroids. Age will divide into 18 and more years old or less than 18.
4.4. Publication bias
Publication bias will be accessed by funnel plot and will use Egger's test (p value of less than 0.05 for a two-sided test) to assess reporting bias when 10 or more studies will be synthesized.
4.5. Sensitivity analysis
We will exclude studies that do not clearly show compliance with the low tidal ventilation strategy and studies with the sequential stopping rule and high risk of bias for the primary outcomes.
Management information
Registered date
| 2020 | Year | 07 | Month | 05 | Day |
Last modified on
| 2020 | Year | 07 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046815
